© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/q3-1-oct-to-31-dec-2023-annb-and-ypa-screening-kpi-data/antenatal-and-newborn-screening-kpi-data-q3-summary-factsheets-1-october-to-31-december-2023
This report should be read in conjunction with the full KPI data tables published each quarter.
1. Fetal anomaly screening
1.1 KPI FA2: coverage: fetal anomaly ultrasound
National performance of FA2 (see standard FASP-SO2) in quarter 2 2023 to 2024 was 98.7%. FA2 is collected 6 months (2 quarters) in arrears.
Quarter 2 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 2 2023 to 2024 | 130,485 | 132,169 | 98.7% |
| Region | Performance % |
|---|---|
| East of England | 99.1% |
| London | 98.1% |
| Midlands | 98.9% |
| North East and Yorkshire | 99.1% |
| North West | 98.7% |
| South East | 98.7% |
| South West | 98.8% |
| England | 98.7% |
1.2 KPI FA3
There is no intention to publish FA3 (see standard FASP-S01) by individual maternity service.
1.3 KPI FA4: combined samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 3 2023 to 2024, national performance of FA4 for inadequate combined samples was 3.7%. FA4 is a KPI where a lower performance is better.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 4,059 | 108,412 | 3.7% |
| Region | Performance % |
|---|---|
| East of England | 2.4% |
| London | 1.5% |
| Midlands | 4.3% |
| North East and Yorkshire | 6.5% |
| North West | 4.1% |
| South East | 4.5% |
| South West | 3.4% |
| England | 3.7% |
1.4 KPI FA4: quadruple samples
FA4 (see standard FASP-SO6) was introduced in 2020 to 2021. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 3 2023 to 2024, national performance of FA4 for inadequate quadruple samples was 7.9%. FA4 is a KPI where a lower performance is better.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 977 | 12,447 | 7.8% |
| Region | Performance % |
|---|---|
| East of England | 4.7% |
| London | 3.2% |
| Midlands | 7.9% |
| North East and Yorkshire | 13.1% |
| North West | 6.3% |
| South East | 13.1% |
| South West | 13.6% |
| England | 7.9% |
2. Infectious diseases in pregnancy screening
2.1 KPI ID1: HIV coverage
National performance of ID1 (see standard IDPS-S01) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 150,994 | 151,262 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.8% |
| North East and Yorkshire | 99.8% |
| North West | 99.8% |
| South East | 99.8% |
| South West | 99.7% |
| England | 99.8% |
2.2 KPI ID2: diagnosis/intervention: timely assessment of women with hepatitis B
National performance of ID2 (see standard IDPS-S06) in quarter 3 2023 to 2024 was 68.6%. The submission of data for ID2 has changed in 2023 to 2024 from maternity service self-reporting to the Integrated Screening Outcomes Surveillance Service (ISOSS) to improve consistency and accuracy of data returns. This has led to an expected reduction in performance as a result of more accurate data, and does not reflect a change in practice for screening providers.
ID2 is a small number KPI, therefore the data should be interpreted with caution.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 109 | 159 | 68.6% |
| Region | Performance % |
|---|---|
| East of England | 81.2% |
| London | 71.1% |
| Midlands | 76.7% |
| North East and Yorkshire | 69.6% |
| North West | 50.0% |
| South East | 66.7% |
| South West | 50.0% |
| England | 68.6% |
2.3 KPI ID3: coverage: hepatitis B
National performance of ID3 (see standard IDPS-S02) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 150,987 | 151,253 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.8% |
| North East and Yorkshire | 99.8% |
| North West | 99.8% |
| South East | 99.8% |
| South West | 99.7% |
| England | 99.8% |
2.4 KPI ID4: coverage: syphilis
National performance of ID4 (see standard IDPS-S03) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 150,985 | 151,256 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.8% |
| North East and Yorkshire | 99.8% |
| North West | 99.8% |
| South East | 99.8% |
| South West | 99.7% |
| England | 99.8% |
3. Sickle cell and thalassaemia screening
3.1 KPI ST1: coverage: antenatal screening
National performance of ST1 (see standard SCT-S01) in quarter 3 2023 to 2024 was 99.8%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 150,862 | 151,161 | 99.8% |
| Region | Performance % |
|---|---|
| East of England | 99.8% |
| London | 99.9% |
| Midlands | 99.8% |
| North East and Yorkshire | 99.8% |
| North West | 99.8% |
| South East | 99.8% |
| South West | 99.6% |
| England | 99.8% |
3.2 KPI ST2: test: timeliness of antenatal screening
National performance of ST2 (see standard SCT-S02) in quarter 3 2023 to 2024 was 61.5%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 93,887 | 152,543 | 61.5% |
| Region | Performance % |
|---|---|
| East of England | 64.4% |
| London | 57.9% |
| Midlands | 55.8% |
| North East and Yorkshire | 71.0% |
| North West | 58.0% |
| South East | 62.5% |
| South West | 65.3% |
| England | 61.5% |
3.3 KPI ST3: test: completion of family origin questionnaire (FOQ)
National performance of ST3 (see standard SCT-S03) in quarter 3 2023 to 2024 was 97.9%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 149,091 | 152,319 | 97.9% |
| Region | Performance % |
|---|---|
| East of England | 97.8% |
| London | 99.7% |
| Midlands | 96.6% |
| North East and Yorkshire | 98.1% |
| North West | 97.5% |
| South East | 97.2% |
| South West | 98.4% |
| England | 97.9% |
3.4 KPI ST4a: referral: timely offer of prenatal diagnosis (PND) to women at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4a (see standard SCT-S05) in quarter 3 2023 to 2024 was 44.9%. Thresholds have not yet been set for this KPI.
ST4a is a small number KPI, therefore the data should be interpreted with caution.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 207 | 461 | 44.9% |
| Region | Performance % |
|---|---|
| East of England | 50.0% |
| London | 48.9% |
| Midlands | 35.3% |
| North East and Yorkshire | 61.4% |
| North West | 37.0% |
| South East | 33.3% |
| South West | 40.0% |
| England | 44.9% |
3.5 KPI ST4b: referral: timely offer of prenatal diagnosis (PND) to couples at risk of having an infant with sickle cell disease or thalassaemia
National performance of ST4b (see standard STC-S05) in quarter 3 2023 to 2024 was 65.6%. Thresholds have not yet been set for this KPI.
ST4b is a small number KPI, therefore the data should be interpreted with caution.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 206 | 314 | 65.6% |
| Region | Performance % |
|---|---|
| East of England | 79.2% |
| London | 72.0% |
| Midlands | 66.2% |
| North East and Yorkshire | 62.3% |
| North West | 52.8% |
| South East | 57.1% |
| South West | 60.0% |
| England | 65.6% |
4. Newborn blood spot screening
4.1 KPI NB1: coverage of CCG responsibility at birth
National performance of NB1 (see standard NBS-S01a) in quarter 3 2023 to 2024 was 97.0%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 134,371 | 138,517 | 97.0% |
| Region | Performance % |
|---|---|
| East of England | 99.7% |
| London | 95.9% |
| Midlands | 96.6% |
| North East and Yorkshire | 97.3% |
| North West | 96.3% |
| South East | 97.6% |
| South West | 96.4% |
| England | 97.0% |
4.2 KPI NB2: test: quality of the blood spot sample
National performance of NB2 (see standard NBS-S06) in quarter 3 2023 to 2024 was 2.6%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 3,536 | 136,979 | 2.6% |
| Region | Performance % |
|---|---|
| East of England | 2.3% |
| London | 2.2% |
| Midlands | 2.5% |
| North East and Yorkshire | 2.9% |
| North West | 2.7% |
| South East | 3.1% |
| South West | 2.4% |
| England | 2.6% |
4.3 KPI NB4: coverage of movers in
National performance of NB4 (see standard NBS-S01b) in quarter 3 2023 to 2024 was 77.6%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 9,821 | 12,657 | 77.6% |
| Region | Performance % |
|---|---|
| East of England | 86.4% |
| London | 68.0% |
| Midlands | 71.5% |
| North East and Yorkshire | 85.9% |
| North West | 83.0% |
| South East | 81.9% |
| South West | 77.5% |
| England | 77.6% |
5. Newborn hearing screening
5.1 KPI NH1: coverage
National performance of NH1 (see standard NHSP-S01) in quarter 3 2023 to 2024 was 98.9%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 146,555 | 148,111 | 98.9% |
| Region | Performance % |
|---|---|
| East of England | 99.3% |
| London | 98.5% |
| Midlands | 99.2% |
| North East and Yorkshire | 98.9% |
| North West | 98.5% |
| South East | 99.2% |
| South West | 99.0% |
| England | 98.9% |
5.2 KPI NH2: diagnosis/intervention – time from screening outcome to attendance at an audiological assessment appointment
National performance of NH2 (see standard NHSP-S05) in quarter 3 2023 to 2024 was 90.6%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 2,336 | 2,578 | 90.6% |
| Region | Performance % |
|---|---|
| East of England | 86.7% |
| London | 93.8% |
| Midlands | 91.0% |
| North East and Yorkshire | 89.9% |
| North West | 85.7% |
| South East | 95.5% |
| South West | 92.9% |
| England | 90.6% |
6. Newborn and infant physical examination screening
6.1 KPI NP1: coverage
National performance of NP1 (see standard NIPE-S01) in quarter 3 2023 to 2024 was 96.3%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 138,421 | 143,740 | 96.3% |
| Region | Performance % |
|---|---|
| East of England | 97.0% |
| London | 96.1% |
| Midlands | 96.2% |
| North East and Yorkshire | 96.3% |
| North West | 95.8% |
| South East | 96.1% |
| South West | 97.4% |
| England | 96.3% |
6.2 KPI NP3: diagnosis/intervention – timeliness of ultrasound scan of the hips for developmental dysplasia
NP3 (see standard NIPE-S03) was introduced in 2021 to 2022. New KPIs are not published in the first year of data collection. This time is used to improve the data quality and completeness, by revising the definition, adding clarity and / or setting thresholds as required.
In quarter 3 2023 to 2024, national performance of NP3 was 74.1%.
Quarter 3 performance
| Reporting period | Numerator | Denominator | Performance % |
|---|---|---|---|
| Quarter 3 2023 to 2024 | 10,177 | 13,726 | 74.1% |
| Region | Performance % |
|---|---|
| East of England | 79.1% |
| London | 72.7% |
| Midlands | 76.3% |
| North East and Yorkshire | 68.4% |
| North West | 70.8% |
| South East | 72.3% |
| South West | 81.9% |
| England | 74.1% |
